- The European Commission has granted Orphan Drug designation to Taysha Gene Therapies Inc's (NASDAQ:TSHA) TSHA-105, AAV9-based gene therapy for SLC13A5-related epilepsy.
- Related: Taysha Gene Secures $100M In Debt Financing For Support Pipeline Development
- SLC13A5 deficiency is a form of infantile epilepsy caused by mutations in the SLC13A5 gene.
- This type of epilepsy manifests as developmental delay and seizures beginning within the first few days of life.
- Orphan designation in the European Union includes benefits such as protocol assistance, reduced regulatory fees, and market exclusivity.
- Related content: Benzinga's Full FDA Calendar
- Price Action: TSHA shares are up 2.88% at $18.33 on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
